Skip to Main Content

Rise and shine, everyone, another busy day is on the way. We can tell because the short person scooted for the local schoolhouse and the official mascots are spending more time than usual fertilizing the Pharmalot grounds. As for us, we are enjoying a warm and shiny sun and, of course, a few cups of stimulation. All of which is to say that the time has come to get cracking. On that note, here are some items of interest to help you along. Have a wonderful day and do keep us in mind when interesting developments emerge …

Express Scripts (ESRX) is pressing drug makers with a new type of migraine treatment to forgo the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates, according to Reuters. The pharmacy benefit manager, which hopes the move alleviates political pressure, is also seeking a refund if the drugs fail to work within a defined timeframe. Amgen (AMGN) expects a drug to be approved next month, followed by similar medicines from Teva Pharmaceutical (TEVA) and Eli Lilly (LLY) that the companies say could benefit up to 4 million people in the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!